Skip to main content
Newsroom

Press Releases and Multimedia

We Strive to Improve Outcomes with Our Novel Adjunctive CKD Therapies

Chronic kidney disease (CKD) is characterized by a gradual loss of kidney function. As many as one in nine U.S. adults has CKD. Kibow Therapeutics is advancing novel, non-invasive therapies to improve quality of life and slow the progression of CKD.